Can-Fite BioPharma

Company Overview

Snapshot

Founded in September 1994 by Ilan Cohn, Can-Fite BioPharma operates with 11–50 employees. The company has raised a total of $113.45 million across 20 funding rounds from 2 investors. In July 2025, Can-Fite BioPharma became publicly traded on the NYSE.

Business overview

Can-Fite BioPharma is an Israeli biopharmaceutical company specializing in the discovery and clinical development of targeted drugs for inflammatory, liver, and metabolic diseases, as well as cancer. The company's core technology leverages the Gi protein-associated A3 adenosine receptor (A3AR) as a therapeutic target, which is highly expressed in pathological cells. Can-Fite's compounds bind to A3AR to modulate NF-kB and Wnt signal transduction pathways, producing anti-inflammatory and anticancer effects. Its pipeline includes proprietary drug candidates such as Piclidenoson (CF101), Namodenoson (CF102), and CF602, serving global markets within the Health Tech & Life Sciences sector.

Strategic signal

In September 2024, Can-Fite BioPharma announced a projected income of $325 million over the next decade following Vetbiolix's exercise of its option to license Piclidenoson for veterinary osteoarthritis. This development signals significant commercial validation for Can-Fite's drug candidates and indicates a strategic expansion into the animal health market, potentially diversifying revenue streams and accelerating product adoption beyond human therapeutics.

Company Intelligence Q&A

What was a significant recent regulatory achievement for Can-Fite BioPharma?

In October 2024, the FDA granted Orphan Drug Designation to Can-Fite’s Namodenoson for pancreatic cancer, recognizing its potential to address a rare disease with high unmet medical need.

What recent patent was granted to Can-Fite BioPharma?

In November 2024, Can-Fite BioPharma secured an Australian patent for its anti-obesity drug, Namodenoson, expanding its intellectual property portfolio in key international markets.

What was a key commercial milestone for Can-Fite BioPharma in 2024?

In September 2024, Can-Fite BioPharma projected an income of $325 million over the next 10 years after Vetbiolix exercised its option and licensed Piclidenoson for veterinary osteoarthritis, indicating a significant commercial partnership.

What clinical trial progress did Can-Fite BioPharma announce in November 2024?

In November 2024, Can-Fite achieved a milestone with the first patient dosing in its Pancreatic Cancer Phase IIa Clinical Trial, advancing the development of Namodenoson for this indication.

When did Can-Fite BioPharma become publicly traded on the NYSE?

Can-Fite BioPharma became publicly traded on the NYSE in July 2025.